Understanding the relationship between GSK-3 and Alzheimer's disease: a focus on how GSK-3 can modulate synaptic plasticity processes - PubMed (original) (raw)
Review
. 2013 May;13(5):495-503.
doi: 10.1586/ern.13.39.
Affiliations
- PMID: 23621307
- DOI: 10.1586/ern.13.39
Review
Understanding the relationship between GSK-3 and Alzheimer's disease: a focus on how GSK-3 can modulate synaptic plasticity processes
Miguel Medina et al. Expert Rev Neurother. 2013 May.
Abstract
Originally discovered because of its role in the regulation of glucose metabolism, GSK-3 is now widely recognized as a crucial player in many cellular functions. Control of GSK-3 activity occurs by complex mechanisms that are each dependent upon specific signaling pathways. Furthermore, GSK-3 dysfunction has been linked to a number of pathologies, including Alzheimer's disease (AD). In particular, the involvement of GSK-3 in several key pathophysiological pathways leading to AD and neurodegenerative diseases has placed this enzyme in a central position in this disorder. In this article, the authors will specifically focus on the role of this enzyme as a key regulator of synaptic plasticity and how alterations in the GSK-3 synaptic functions may be a major factor in AD and other neurodegenerative disorders.
Similar articles
- New insights into the role of glycogen synthase kinase-3 in Alzheimer's disease.
Medina M, Avila J. Medina M, et al. Expert Opin Ther Targets. 2014 Jan;18(1):69-77. doi: 10.1517/14728222.2013.843670. Epub 2013 Oct 8. Expert Opin Ther Targets. 2014. PMID: 24099155 Review. - Glycogen synthase kinase-3 as a key regulator of cognitive function.
Fan X, Zhao Z, Wang D, Xiao J. Fan X, et al. Acta Biochim Biophys Sin (Shanghai). 2020 Mar 18;52(3):219-230. doi: 10.1093/abbs/gmz156. Acta Biochim Biophys Sin (Shanghai). 2020. PMID: 32147679 Review. - Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease.
Medina M, Avila J. Medina M, et al. Curr Pharm Des. 2010;16(25):2790-8. doi: 10.2174/138161210793176581. Curr Pharm Des. 2010. PMID: 20698823 Review. - GSK-3 and Tau: A Key Duet in Alzheimer's Disease.
Sayas CL, Ávila J. Sayas CL, et al. Cells. 2021 Mar 24;10(4):721. doi: 10.3390/cells10040721. Cells. 2021. PMID: 33804962 Free PMC article. Review. - Synaptotoxicity in Alzheimer's disease: the Wnt signaling pathway as a molecular target.
Inestrosa NC, Varela-Nallar L, Grabowski CP, Colombres M. Inestrosa NC, et al. IUBMB Life. 2007 Apr-May;59(4-5):316-21. doi: 10.1080/15216540701242490. IUBMB Life. 2007. PMID: 17505971 Review.
Cited by
- Protein phosphatase 2A dysfunction in Alzheimer's disease.
Sontag JM, Sontag E. Sontag JM, et al. Front Mol Neurosci. 2014 Mar 11;7:16. doi: 10.3389/fnmol.2014.00016. eCollection 2014. Front Mol Neurosci. 2014. PMID: 24653673 Free PMC article. Review. - SARS-CoV-2 propagation to the TPH2-positive neurons in the ventral tegmental area induces cell death via GSK3β-dependent accumulation of phosphorylated tau.
Imai M, Kawakami F, Uematsu T, Matsumoto T, Kawashima R, Kurosaki Y, Tamaki S, Maehana S, Ichikawa T, Hanaki H, Kitazato H, Kubo M. Imai M, et al. PLoS One. 2024 Oct 30;19(10):e0312834. doi: 10.1371/journal.pone.0312834. eCollection 2024. PLoS One. 2024. PMID: 39475992 Free PMC article. - SHMT2 Mediates Small-Molecule-Induced Alleviation of Alzheimer Pathology Via the 5'UTR-dependent ADAM10 Translation Initiation.
Song L, Pan QL, Zhou GF, Liu SW, Zhu BL, Lin PJ, Hu XT, Zha JS, Long Y, Luo B, Chen J, Tang Y, Tang J, Xiang XJ, Xie XY, Deng XJ, Chen GJ. Song L, et al. Adv Sci (Weinh). 2024 Mar;11(11):e2305260. doi: 10.1002/advs.202305260. Epub 2024 Jan 6. Adv Sci (Weinh). 2024. PMID: 38183387 Free PMC article. - The key genes, phosphoproteins, processes, and pathways affected by efavirenz-activated CYP46A1 in the amyloid-decreasing paradigm of efavirenz treatment.
Petrov AM, Mast N, Li Y, Pikuleva IA. Petrov AM, et al. FASEB J. 2019 Aug;33(8):8782-8798. doi: 10.1096/fj.201900092R. Epub 2019 May 7. FASEB J. 2019. PMID: 31063705 Free PMC article. - Bi-directional genetic modulation of GSK-3β exacerbates hippocampal neuropathology in experimental status epilepticus.
Engel T, Gómez-Sintes R, Alves M, Jimenez-Mateos EM, Fernández-Nogales M, Sanz-Rodriguez A, Morgan J, Beamer E, Rodríguez-Matellán A, Dunleavy M, Sano T, Avila J, Medina M, Hernandez F, Lucas JJ, Henshall DC. Engel T, et al. Cell Death Dis. 2018 Sep 20;9(10):969. doi: 10.1038/s41419-018-0963-5. Cell Death Dis. 2018. PMID: 30237424 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical